Neurocrine Biosciences | NBIX - Bénéfice Avant Impôts





Bénéfice Avant Impôts Changement Date
AbbVie USD 4.38B 1.92B 2025-09
Acadia Pharmaceuticals USD 26.32M 18.28M 2025-12
Agios Pharmaceuticals USD -109.06M 5.62M 2025-12
ALKERMES USD 100.74M 4.1M 2025-09
Alnylam Pharmaceuticals USD 161.14M 77.83M 2025-12
Amgen USD 3.92B 2.35B 2025-09
Biogen USD 557.3M 186.7M 2025-09
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Cytokinetics USD -183.03M 123.15M 2025-12
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
Exelixis USD 252.69M 275K 2025-12
Gilead Sciences USD 3.64B 1.21B 2025-09
Halozyme Therapeutics USD 218.96M 14.02M 2025-09
Incyte USD 389.94M 92.37M 2025-12
Ionis Pharmaceuticals USD -228M 99M 2025-12
Nektar Therapeutics USD -37.05M 15.27M 2024-09
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
Pfizer USD 3.33B 290M 2025-09
Prothena USD -21.58M 15.33M 2025-12
Regeneron Pharmaceuticals USD 1.76B 244.6M 2025-09
Repligen USD 17.11M 10.25M 2025-09
Rigel Pharmaceuticals USD -1.03M 7.22M 2024-06
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
Teva Pharmaceutical Industries USD 91M 555M 2025-12
Ultragenyx Pharmaceutical USD -128M 51.54M 2025-12
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09
Xoma USD 15.98M 24.58M 2024-06